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Abstract 
We have isolated and sequenced the L-arginine:glycine amidinotransferase of pig kidney mitochondria. Due to endogenous proteolysis, the purified 
molecules howed some heterogeneity at the N terminus. The longest form recovered had 386 amino acids. Part of the pig amidinotransferase quence 
information was used to isolate cDNA clones coding for the human enzyme. The deduced amino acid of the human amidinotransferase was 37 amino 
acids longer due to the presence of a signal sequence. The mature proteins were 94% identical to each other and 36% identical to the sequences of 
bacterial L-arginine:inosamine phosphate amidinotransferases. 
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1. Introduction 
L-Arginine:glycine amidinotransferase (EC 2.1.4.1) 
catalyzes the transfer of a guanido group from arginine 
to glycine. The resultant guanidoacetic acid is the imme- 
diate precursor of creatine [l]. Creatine and its 
phosphorylated form play an important role in the en- 
ergy metabolism of muscle and nerve tissues, acting as 
a dynamic reservoir of high-energy phosphate, which 
buffers the rapid fluctuations of the ADP/ATP ratio dur- 
ing muscle and nerve action [2]. Interestingly, creatine is 
not synthesized in those tissues that have the largest 
pools of creatine and creatine phosphate but must be 
taken up from the blood. The major sites of creatine 
biosynthesis are pancreas, kidneys and liver, where the 
amidinotransferase seems to be located in the mitochon- 
dria of cells [3-51. It has been suggested that amidi- 
notransferase activity in these tissues is regulated in a 
number of ways including induction by growth hormone 
and thyroxine [6], inhibition of the enzyme by ornithine 
[7] and repression of its synthesis by creatine [8]. Transfer 
of guanido groups is also known in Streptomyces bacte- 
ria where L-arginine:inosamine phosphate amidinotrans- 
ferases catalyze two reactions in streptomycin biosynthe- 
sis [l]. The amino acid sequences of the bacterial en- 
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.466rewations: APMSF, 4-aminophenyl methanesulfonyl fluoride; 
DTT, dithiothreitol; PMSF, phenylmethanesulfonyl fluoride; TLCK, 
tosyl lysine chloromethyl ketone; TPCK. tosyl phenylalanine chloro- 
methyl ketone. 
zymes have been derived by cDNA sequencing [9-l 11. In 
contrast, no sequence has been reported for eukaryatic 
amidinotransferases. The present report fills this gap. 
2. Materials and methods 
2. I. Isolation of porcine amidinorransferase 
Fresh porcine kidney cortex was cut in small pieces and suspended 
in ice-cold homogenization buffer (250 mM saccharose, 10 mM trietha- 
nolamine, 10 mM EDTA, 10 mM glycine, 5 mM DTT, 1 mM dipyridyl, 
1 mM l,lO-phenanthroline, 1mM PMSF, 1 mM iodoacetamide, 1mM 
iodoacetate, 0.02 mM TLCK, 0.04 mM TPCK, 0.016 mM APMSF, 
0.5 mM p-chloromercuribenzoate, 2 mM sodium citrate, 0.0065 mM 
bestatin, pH 7.5) while still in the slaughter house. The cortex pieces 
were then homogenized in a Waring blender for 2 min and filtrated 
through gauze. This homogenate was then centrifuged at 940 x g for 10 
min. The supematant was centrifuged at 1,760 x g for 15 min and the 
resulting supematant was finally centrifuged at 11,000 x g for 90 min. 
The pellet was resuspended in the same buffer and the last centrifuga- 
tion was repeated. The final mitochondrial fraction, resuspended in 
homogenization buffer, was then centrifuged in a discontinuous gradi- 
ent of 55 ml, 20 ml and 5 ml of 33,44 and 50% saccharose in 10 mM 
triethanolamine, pH 7.5, and protease inhibitor mixture (10 mM 
EDTA, 2 mM DTT, 0.1 mM dipyridyl, 0.1 mM phenanthroline, 0.5 
mM PMSF, 0.5 mM iodoacetamide, 0.5 mM iodoacetate, 0.02 mM 
TLCK, 0.04 mM TPCK, 0.005 mM APMSF, 0.2 mM p-chloromercu- 
ribenzoate, 1 mM sodium citrate, 0.0065 mM bestatin) in 100 ml centri- 
fuge tubes at 54,000 x g for 11 h. The mitochondrial fraction collected 
from the 33144% interface was then brought to 0.6 M NaCl and soni- 
cated 2 x 5 min in a Branson sonicator model 250 at setting 8 with a 
large tip. The sonicated homogenate was then centrifuged at 35,000 x g 
for 2 h. The supernatant was applied to a phenyl sepharose column 
(19 x 1.4 cm) equilibrated in 50 mM Tris, pH 7.5, containing 0.6 M 
NaCl and a 1:l dilution of the protease inhibitor mixture. Bound pro- 
tein was eluted with a linear gradient from 0.6 to 0.05 M NaCl in the 
same buffer. Fractions containing amidinotransferase activity were di- 
luted with the same volume of water and further separated on a hydr- 
oxyapatite column (30 x 1.4 cm) in 30 mM potassium phosphate, pH 
7.5, containing the protease inhibitor mixture in a 1:50 dilution, with 
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a linear gradient up to 0.5 M potassium phosphate. The same dilution 
of protease inhibitors was used in all subsequent steps. Fractions con- 
taining amidinotransferase activity were brought to pH 8.5 with Tris 
and dialyzed against 20 mM Tris, pH 8.5, containing the usual protease 
inhibitors. The enzyme solution was then further separated by chrom- 
atography on DEAE-cellulose (Whatman DE-52) in 25 mM Tris, pH 
8.5, and protease inhibitors, with a gradient from 0 to 0.5 M NaCl. The 
enzyme was concentrated in an Amicon ultrafiltration cell using a YM 
30 membrane and finally purified by size exclusion chromatography on 
a Superose 12 column (Pharmacia) equilibrated in 150 mM potassium 
phosphate, pH 7.5, with protease inhibitor mixture. All purification 
steps were carried out in the cold room, except gel filtration. Each step 
was monitored by determining the enzymatic activity [12] and the pro- 
tein concentration [13]. SDS-PAGE was as in [14]. 
2.2. Isolation of peptides and sequence analysis 
The purified protein was reduced and pyridylethylated under dena- 
turing conditions [15]. The reaction mixture was then dialysed against 
0.2 M ammonium hydrogen carbonate. During dialysis the protein 
precipitated. A sample of this suspension was treated with lysyl en- 
dopeptidase (Wako Chemicals, Neuss, Germany) at an enzyme/sub- 
strate ratio of 1:lOO (w/w) at 23°C for 16 h. The reaction was terminated 
by acidification with a drop of concentrated trifluoroacetic acid and 
1:20 dilution with 0.1% trifluoroacetic acid. Soluble and insoluble frag- 
ments were separated by centrifugation with an Eppendorf bench top 
centrifuge. The soluble peptides were separated by reversed phase 
HPLC (Vydac C18,4.6 mm x 250 mm column) using 0.1% trifluoroace- 
tic acid (A) and 0.1% trifluoroacetic acid in 70% acetonitrile (B) with 
a gradient from 0% to 60% B in 160 min at a flow rate of 0.25 ml/min. 
The same procedures were subsequently used with all cleavage mix- 
tures. The pelleted fragments were dissolved in 8 M urea and diluted 
with 0.2 M ammonium hydrogen carbonate to 1 M urea before adding 
lysyl endopeptidase as above. The insoluble fragments obtained by this 
second treatment with the same enzyme were dissolved in concentrated 
formic acid and sequenced. The soluble peptides were separated by 
HPLC. Another portion of the pyridylethylated protein was suspended 
in 0.2 ammonium hydrogen carbonate containing 20% acetonitrile and 
cleaved with endoproteinase Asp-N (sequencing rade, Boehringer 
Mannheim, Germany) at an enzyme/substrate ratio of 1:50 at 23°C. 
After 8 h the same amount of enzyme was added once again and the 
reaction was allowed to continue for a further 16 h. The peptides oluble 
in 0.1% trifluoroacetic acid were separated by HPLC. The insoluble 
fragments were divided in three portions, one of which was sequenced. 
The others were suspended in 0.2 M ammonium hydrogen carbonate 
and cleaved with thermolysin (Merck, Darmstadt, Germany) for 3 h or 
chymotrypsin (sequencing rade, Boehringer Mannheim) for 2 h both 
at 30°C with an enzyme/substrate ratio of 1:50. The peptides were 
separated by HPLC. Another sample of the amidinotransferase was 
cleaved in 7 M guanidine. HCl dissolved in 75% formic acid at 37°C 
for 60 h [16]. The reaction mixture was then diluted and soluble and 
insoluble fragments separated as above. A sample of the insoluble 
fragments was sequenced while another part was further cleaved, either 
m 75% formic acid by addition of a small crystal of CNBr and incuba- 
tion at 23°C for 24 h under nitrogen in the dark, or with endoproteinase 
Asp-N in 20% acetonitrile as above. Peptides insoluble in 0.1% tri- 
fluoroacetic acid were sequenced, the soluble peptides were separated 
by HPLC. Sequence analysis of soluble and insoluble peptides was done 
by Edman degradation using Applied Biosystems equencers 470A and 
473A according to the manufacturer’s instructions. 
2.3. Isolation of human cDNA and sequence analysis 
A 1047-bp fragment coding for a partial arginine:glycine amldi- 
notransferase sequence was isolated and amplified by PCR from a 
1Uni-Zap cDNA library (Stratagene Cloning Systems) constructed 
with mRNA from human kidney carcinoma cells using primers synthe- 
sized according to the porcine amino acid sequences 32-41 and 371-380 
(Fig. 2). An XhoI and a PstI restriction site sequence were introduced 
at the 5’ and at the 3’ end (Fig. 3). PCR was used with 50 pmol primers 
in 50 ~1 standard buffer with 200 PM deoxynucleotides (Perkin-Elmer 
480), and 3 U Taq polymerase. 30 cycles were run with an annealing 
temperature of 55°C. The amplified fragment was restricted with XhoI 
and PstI and cloned into pUC19 (Gibco BRL). Labeled fragment was 
produced by random priming [17,18] using a purchased kit (United 
States Biochemical Corp.). The labeled fragment was used to screen the 
AUni-Zap library according to established procedures [19]. 5 positive 
phage clones (AT1 to AT5) were subcloned into pBluescript SK- (Strat- 
agene). Nucleotide sequencing was performed with Sequenase (United 
States Biochemical Corp.) or using an Applied Biosystems equencer 
373A with the Prism Ready Reaction Dye Deoxy Terminator Cycle 
Sequencing kit. Both strands were sequenced to obtam complete nucle- 
otide sequences of clones AT1 and AT5. 
3. Results and discussion 
3.1. Isolation and sequence analysis of porcine 
amidino-transferase 
First attempts to isolate the amidinotransferase were 
undertaken with homogenized kidney tissue. This 
yielded molecules with heavily truncated N-terminal 
ends. Only purification of the enzyme from isolated mi- 
tochondria yielded two major N-terminal amino acid 
sequences (Figs. 1 and 2). These sequences were con- 
firmed later with peptides and are indicated in Fig. 2 
above the first row of amino acid sequence. Because we 
were not able to prevent this proteolytic degradation 
during purification of the enzyme with protease inhib- 
itors, we do not know with certainty whether the longest 
form we recovered, and which is shown in Fig. 2, actually 
represents the intact molecule. The purification proce- 
dure described above resulted in a 280-fold enrichment 
of amidinotransferase activity with a final yield of 8%. 
SDS-PAGE (Fig. 1) showed two closely spaced bands of 
M, 46,000. This heterogeneity was probably due to par- 
tial N-terminal degradation. 
Sequence analysis was hampered by the low solubility 
of the denatured and pyridylethylated or carboxymethyl- 
ated enzyme in solvents suitable for proteolytic degrada- 
tion. A first cleavage experiment with lysyl endopepti- 
dase yielded some peptides which were soluble in re- 
692kDa 
-68kDa 
-45kDa 
-29kDa 
Fig. 1. SDS-PAGE of purified pig kidney arginine:glycine arnldi- 
notransferase on a 12% gel. The positions of marker proteins are shown 
on the left (phosphorylase b, bovine serum albumin, ovalbumin and 
carbonic anhydrase). 
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versed phase HPLC starting solvent (numbered K pep- 
tides in Fig. 2). Sequence analysis of the insoluble frag- 
ments showed them to be a very heterogeneous mixture. 
A second digest in the presence of urea yielded some 
more soluble peptides (K peptides with small letters in 
Fig. 2) and also an insoluble residue which yielded two 
major sequences (Klins and K2ins, Fig. 2). Next, the 
amidinotransferase was exhaustively digested with en- 
doproteinase Asp-N. Apart from the soluble peptides (D 
peptides in Fig. 2), this yielded an insoluble residue 
which could be solubilized by degradation with either 
thermolysin or chymotrypsin. These rather unspecific 
proteases cleaved the substrate into a heterogeneous 
mixture of mostly very short peptides. However, se- 
quence analysis of the major peaks after reversed phase 
HPLC separation of the peptides yielded some valuable 
information (TH and CH peptides in Fig. 2). The se- 
quence data available at that time indicated a favorable 
number and distribution of AspPro bonds which could 
be cleaved by limited acid cleavage in 75% formic acid 
1 
51 
101 
151 
201 
251 
301 
351 
;___________________________> 
I_____________________> 
STQAATASSGNSCAADDKATDPLPKDCPVSSYNEWDPLEEVIVGRAENAC 
;____ K3 ___) ~_~~~~~~~~~-~~~---~~~~ K17 ___________------___-- 
I___ D2 __I )______ Dllb -----; ;__________________ D23 ----- 
I_____________________ Hl ______________; ;____________ H3 ___________; ;__-_--------- H4 --------- 
;___________ El4 ________----___---> 
VPPFTVEVKANTYEKYWPFYQKYGGHYFPKDHLKKAVAEIEENCNILKNE 
1 I__ K2 ____________----, , ___I I___ Kll ___; I____ K6 _____I IKlb _I ;________ Kl3a _____----I 1-m 
1 ________________________I , I_____________ Dl8b ____________; 
______________~~~~~~~~~~~~~-~-_________~~~~~~~~~~~~~~~~~~~> 
!_____________ El3 ________________----~-~-~~-~~ ;____ E9 _____I 
GVTVRRPDPIDWSVKYKTPDFESTGLYGANPRDILIVVGNEIIEAPNAWR 
________ Kg ________________~ I___---________--___ Klins --------------------> 
;__________________ El2 ____________~ ~_________ Dins ___________________ 
I________ Hlins _____---__-__-_-_> 
;______ CH16 _________; 
I______________ CDins ----_-_-~-~ I__-- 
ARFFEYRAYRSIIKDYFRRGAKWTTAPKPTNADELYDQDYPIYSVEDRHK 
I______ Kb ___I ~_________________ a _____________________________> ; 
____-_--~-~-----> ;_______________ DlDb ____________; I-D6 _I I_______ DlDc ____I I______ 
(- CH6 -I I-- CHll ---I ;_________ CH28 ________________; 
~________ TH 36 __________; I__ TH2 __I 
__ CB22 ~~~~~~~~~~---~-----------> 
LAAQGKFVTTEFEPCFDAADFIRAGRDIFAQRSQVTNYNGIEWNRKHLAP 
__ Kla ___I ~~~-~~-~~~-~~~~~~-______ K2ins _____________-_> )______ 
_____________ DlGa ___________; (____ D7 ___I I____________ D24a _______________________> 
I_ CH3 ___I ;--__----_ CH27 __________; ;-mm CH15 ____; ;-m__ CH5 _-__-m~ I_ CH22 -1 I--- CHlDa _ 
I___ TH21 __I I___ TH25a __I I_______ TH37 ________~ I_____ THl5a __I I___ TH33 ____) I______ 
;__________ 
DYRVHIISFKDPNPNHIDATFNIIGPGLVLSNPDRPCHQIDLFKKAGWTI 
-- Ki 1 I_______________ K,. _____-____--_-__-~~~-~> ____________, , I __-_-__- 
I______ D15 -_----~ I-__ Dg ___-I ~_________________ D22a ___~~~~~~~~~~~~~~~~~~ ~--~-____------_--- 
___--_-> ~~-~~~~~~~~~~~-~~-~~~--~~--~ H2ins _____~_~~~~~~~~~~~~~~~~~~~~~~~~> 
-TH16a --I )___ TN32 ____I I--- CH27b -I ;_-------_ CH2Db ----_--; I- CH7 _I I-- 
____ CBl6 _________________~ ~______ TH24 ---------~ ~-_--- TH39a -_--_I 
VTPPIPVIPDDHPLWNSSKWLSHNVLULDEKRVMVDANEVPIQKNF~KLG 
-_--_______ KS _---mm-____________> 
-____ Dins _____________________> 
I------ Kp -----------~ I__-_-______ K7a _______I 
(--- D4b ---I ~_________ D27 ___________!:: 
------ CH33 -------------__--~ I__ CRlla __I 
~_________ CH26 __________> 
I---_____________ E22 __________I 
;______ 
ISTIKISIRNANSLGGGFHCWTCDVRRRGTLQSYFD 
-- K7b -I I-----------------------_ Kl3b,b ________________________> 
1' CH27a ______________________> 
~_________ Dl2 _________; 
~______ H2 ___________I 
I--------___ CHl6b _________; 
Fig. 2. Amino acid sequence of pig kidney arginineglycine amidinotransferase. Dashed lines identify positions sequenced by Edman degradation 
and are terminated by a vertical ine in case of complete sequence determination or by an arrow in the case of partial sequence determination. The 
lines above the first row of sequence indicate the major N-terminal sequences found. Individual peptides were generated by cleavage with cyanogen 
bromide (CB), chymotrypsin (CH), endoproteinase Asp-N (D), formic acid (H), lysyl endopeptidase (K), or thermolysin (TH) and are distinguished 
by numbers or small letters according to different chromatographic pools. ins means insoluble in RP-HPLC starting solvent. 
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containing 7 M guanidine. The cleavage of the substrate 
was nearly complete and highly specific. Apart from the 
Asp-Pro bonds only an AspVal bond (374/375, Fig. 2) 
was cleaved to some extent. The reaction mixture con- 
tained the peptides Hl to H4 soluble in HPLC starting 
solvent and the insoluble larger fragments Hlins and 
H2ins (Fig. 2). The latter were further cleaved by CNBr 
or endoproteinase Asp-N to yield the insoluble peptides 
Dins and CBins (Fig. 2). Screening of the soluble CNBr- 
peptides (CB peptides in Fig. 2) eventually yielded the 
final sequences needed to assemble the complete amino 
acid sequence of porcine arginine:glycine amidinotrans- 
ferase. 
The porcine arginine:glycine amidotransferase con- 
tained 386 amino acids giving a molecular weight of 
44,188, which is in good agreement with the apparent 
molecular weight obtained by gel electrophoresis (Fig. 
1). No signs of post-translational modification of amino 
acids were found. A search for known sequence motifs 
(using the Prosite Dictionary of Dr. A. Bairoch, Geneva) 
did not yield any meaningful result with the possible 
exception of the presence of an incomplete mitochon- 
drial energy transfer proteins signature [20,21] between 
positions 78 and 88. This sequence motif was only found 
in mitochondrial membrane proteins, where it occurs 
several times. The presence of one incomplete copy of 
AS1 Y 
this motif in the amidinotransferase is probably insignif- 
icant. 
3.2. Isolation of human cDNA clones and sequence 
analysis 
When it became clear that we could not isolate a ho- 
mogeneous population of porcine amidinotransferase 
molecules suitable for crystallization, we began experi- 
ments aiming at the recombinant production of the en- 
zyme. A fragment of cDNA was isolated from a human 
kidney carcinoma cDNA library by PCR using oligonu- 
cleotide primers synthesized according to the porcine 
protein sequences 3241 and 371-380 (Fig. 3). This frag- 
ment of 1047 bp was labeled and used to identify longer 
clones in the same library. 5 positive clones were isolated, 
the inserts subcloned and characterized by partial se- 
quencing. The deduced amino acid sequences were 
highly similar to sequences of the porcine enzyme. 4 
clones were near full-length (ATl-AT4), 1 started with 
nucleotide 166 of the complete clones (AT5). The com- 
plete nucleotide sequence of a near full-length clone 
(ATl) and the derived amino acid sequence are shown 
in Fig. 4. The human cDNA-derived protein sequence is 
37 amino acids longer than the longest porcine form. 
This is clearly due to the presence of a leader peptide 
(Figs. 4 and 5). However, it is difficult to predict the 
N E W D P L E E V 
5' PCR-primer GCGA TCTAGA TAY AAY GAR TGG GAY CC1 CT1 GAR GAR GT 
Xho I 
AS2 WTCDVRRRGT 
NS TGG AC1 TGY GAY GTI MGI MGI MGI GGI AC1 
3' PCR-primer GCGT CTGCAG GGT ICC ICK ICK ICK IAC RTC RCA IGT CCA 
Pst I A 
Sac11 XhoI 
Eco RI Nde I Nco I HmcII Hind111 
I I I I I I 
KpnI 
Y////////////////////////~ 
I I 
1 400 800 1200 1600 2000 
A- b-- 
-- - -- 
--- 4 
4 l l 
B 
Fig. 3 (A) Oligonucleotide primers used for PCR.ASl, amino acids 3241 of the pig amidinotransferase; AS2, amino acids 371-380. NS, nucleotide 
sequence deduced from AS2. The 3’ primer is the inverse complement of this sequence. I, inosine; R, purine; Y, pyrimidine; K, bases G or T; M. 
bases A or C. Both primers were synthesized with a restriction site as indicated. (B) Partial restriction map and sequencing strategy used to obtain 
the nucleotide sequence of a near full-length human arginine:glycine amidinotransferase cDNA clone. Arrows indicate sequenced regions and direction 
of sequencing. The hatched area indicates the position of the open reading frame. 
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-69 GM TX CGC ACC AGC GAC GCG GCC CAG AQ CCA CGA ACA lTC CGC GCG TGG ACC AGC CGG CCC AC.5 CCC ATG CTG CGG GTG CCC TGT CTG 
MLRVRCL 7 
22 CGC GGC GGG AGC CGC GGC GCC GAG GCG GTG CAC TAC ATC GGA TCT CGG Cl? GGA CGA ACC TTG ACA GGA TGG GYG CAG CGA ACT TTC CAG 
R G G S R G A E A V H Y I G 5 R L ii R T L T G W V Q Ii T F Q 37 
112 AK ACC CA6 CC4 GCT ACG GCF TCC TCC CGG AAC TCC Tcf GCA GCT GAC GAC MA CCC ACT GAG CCT CTG CCC AAG GAC TM: CC-! tic TCT 
S T Q A AT A 5 5 R N S C A A D D K A T E P L P K D C P V S 67 
262 TCT TAC MC GM TGG GAC ccc TTA GAG CM GTG ATA GTG GGC AGA GCA GM MC GCC TGr 0-r CCA CCC TTC ACC ATC GAG GTG MG CCC 
SYNEWDPLEEVIV G R A E N A C V P P F T I E V K A 97 
292 MC ACA TAT GM AAG TAC TGG CCA TTT TAC CAG AAG CM CGA GGG CAT TAT l-ll CCC AdA GAT CAT TTG AAA AAC Gff GlT GCT GM AlT 
NTYEKYWPFYQKQ G G H Y F P K D H L K K A V A E I 127 
362 GAA CAA ATG TGC AAT An TTA AM ACG GAA CGA GTG ACA GTA AGG AGG CCT GAC CCC Al? GAC TGG TCA TTG AAG TAT AAA ACT CCT GAT 
E EMCNIL KTEGVTVR R P ff P I 0 W 5 L K Y K T P D 157 
472 TTT GAG XT ACG GGT TTA TAC Am GCA ATG CCT CGA GAC ATC CTG ATA GTY GTG GGC MT GAG AlT ATE GAG GCT CCC ATG GCA TGG CGT 
F ESTGLY S AM P R D I L I V V G N E I I E A P II A W R187 
562 TCA CCC TTC TlT GAG TAC CGA GCG TAC AGG TCA AIT ATC AM GAC TAC TX CAC CGI GGC GCC AAG TGG ACA AC& GCT CCr MC CCC ACA 
SRFFEYRAYRSII KDYFHRGAKWTTAPK P T 227 
652 ATG GCT CAT GAG CTT TAT MC CAG GAT TAT CCC ATC CAC TCT GTA GM GAC AGA CAC AA4 TTG GCT GCT CAG GGA AAA Tll GTG ACA ACT 
MADELY NQDYPIH SVEDRHKLAA Q C K F V T T 247 
742 GAG Y?l’ GAG CCA TGC Tll CAT ttr GCT GAC TYC ATY CGA GCT GGA AGA GAT ATT Tl? GCA CAG AGA AGC CAG Gil RCA AAC TAX CTA GGC 
E F EPCFDAA DFIRAGRDI F A Q R 5 Q V T N Y L G 277 
832 ATT GAA TGG ATG CGT AGG CAT CTT GCT CCA GAC TAC AGA GTG CAT ATC Ax. TCC TTT AM GAT CCC AAT CCC ATG CAT ATT GAT GCF ACC 
I E W M R R H L A P D Y R V H I I S F K D P N P W H I D AT367 
922 TTC AAC ATC Al-F GG4 CCT GCT AiT GTG Cl?’ TCC #AC CCT GAC CGA CCA TGT CAC CAG All GAT CTI TTC AAG AM GCA CGA TGG ACT ATE 
FNIIGPGIVLSNPDRPCHQIDL F K K A G W T I 337 
1612 All ACT CCT CCA ACA CCA ATC ATC CCA GAC CAT CAT CCA CTC TGG ATG TCA TCC AAA TGG CTT TCC ATG MT GYC TTA ATG CTA GAT GAA 
ITPPTP IIPDDHPLWHSSKWL 5 M N V L M L D E 367 
1102 AAA EGT GlT ATG GTG GAT GCC AAT GM Cl? CCA ATT CM AAG ATG llT GM AAG CTG G(;r ATC ACT ACC All AM GYl MC ATT CtT MT 
K R V M V D A N E VPIQKMF E K L GITTIKVNI R N 397 
1192 GCC RAT TCC CTG CGA G&A GGC TTC CAT TGC TGG ACC TGC GAT GTC EGG CGC CGA GGC ACC CTA CL TCC TAC YTG GAC TGA RCA GGC CTG 
A N S L GGGFHCWTCDVRRRGTLQSYLD* 423 
1282 ATG GAG CTT GTG GCT GGC CTC AGA TAC ICC TM GM GCT TAG GGG CAA GGY TCA TTC TCC TGC Tll AM AAG TGC ATG AAC TGT AGT GCT 
1372 TTA MC AAT CAT CTC CTf MC AGG GGT CGT AAG CCT GGT TTG Cl? CTA TTA CTT TTC TlT GAC ATA MG AAA ATA AC? TCT GCT AGG TAT 
1462 TAC TCI’ CTA CTC CTA AAG TTA m ACT ATT TGG Cl-T CM GTA TAA MT Tll CGT GM TGT GTA CCA AGA AM MT TAG TCA CCT GAG TAA 
1552 CTT GGC CAC TM TM TTA ACC ATC TAC CTC TGT TTT TM TTT TCT TrC CM AAG GCA GCT TGA MT GTT GGT CCY MT ClT MT TlT TlT 
1642 TCC TCI TCT ATA GAC TTG AGA ATG TTT TX TCT AAA TGA GAG AM GAC TTA GM TGT ACA CAG ATC CM AAT AGA ATC AGA IfA TCl CTT 
1732 TTT TTC SAA AGG AGA GM AGA CTr A@. ACA TAC ACA GAT CO AAG TAG AAC CAG GTA ATf FC TCT TTT TCY MT AA6 GAA Til GGG TAA 
1822 ~~AA~~T~m~A~~T~C~A~CTATG~~~TC~A~~mTCCATG~T~~MTA~~CATCT~ 
1912 ACA TTG TGA TAT ATG CTA CTA AM ACC TT, TCA TAT ACA TCT TAC CTC ATT TCA AGT GAA TTA T,T TM TCT ‘“T TCr CTC TTT CCA AAh 
2602 ATY TAC AGG MT GTT TAG TGT MT TGG ATT TCG CTA TCA GIT CCC ATC CTT MC TTT TGA TAT TCA ATA TCT GAT AGA TAC ACT GCA TCT 
2692 TTG CTC ATC TM CAT ITG m ACA MT GTG CM AT, An TAG AGC ATA GAC TTT ATA AGC A,T AAA AAA MC TM TGG AGG TM MC CTA 
2182 AAT GCG ATG TGA AAT MT TTr AGT GTT GAT ACT GTA TGT GTA TTr TTA YTC TM TM ACT TT-f GTG TTC CAG AT, GM AA 2262 
Fig. 4. Nucleotide sequence and deduced amino acid sequence of a human L-arginine:glycine amidinotransferase cDNA near full-length clone. 
Nucleotides are numbered on the left, amino acids on the right. The polyadenylation sequence is underlined. 
exact cleavage site between leader sequence and mature 
protein. Recently a survey of N-terminal proteolytic 
cleavage sites in mitochondrial precursor proteins has 
identified a motif consisting of an arginine at position 
-10, a hydrophobic amino acid at position -8 and a 
serine, threonine or glycine at position -5 relative to the 
mature amino terminus [ZZ]. The N-terminal region of 
the human precursor molecule contains exactly this 
motif with Arg-34, Phe-36 and Thr-39. However, with 
the cleavage site predicted in this way, between Thr-43 
and Ala-44, the mature human enzyme would be 6 amino 
acids shorter than the longest porcine form. Another, 
although not perfect, motif may include Arg-26 and Leu- 
28 but would lack the canonical residue at position -5. 
This imperfect motif would predict cleavage between 
Thr-35 and Phe-36 resulting in a mature protein 2 amino 
acids longer than the longest porcine species found in 
mitochondrial preparations. Thus the exact location of 
the precursor cleavage site remains unclear. Leaving 
aside the putative leader sequence, the human and por- 
cine amidinotransferases are 94% identical, with most of 
the changes being conservative amino acid replacements 
(Fig. 5). 
3.3. Comparison to other proteins 
When compared with the FASTA program 1231 to 
106 
HUMAN 1 MLRVRCLRGGSRGAEAVHYIGSRLGRILTGWVQRTFQ 
HUMAN 38 PIG 1 STQAATASSGNSCAADOKATDPLPKDCPVSSYNEWDPL~EVIVGRAENAC 
strBl 1 
STQAATASSRNSCAADDKATEPLPKDCPVSSYNEWDPLEEVIVGRAENAC 8 
strl?. 1 
MvL~SVH1,,,.,,,,1],o,[VGA@ 
MSLVGVHNEWDPLEEVVVGTARRP@ 
Fig. 5. Alignment of mammalian arginine:glycme amidinotransferase quences to bacterial arginine:inosamine phosphate amidinotransferases strB1 
[lo] and strB2 [I 11. Boxes enclose amino acids identical in all 4 sequences. Cysteines are in circles. 
known protein sequences compiled in the MIPSX 
(Martinsried Institute for Protein Sequences) data collec- 
tion, the mammalian enzymes were found to be very 
similar to the bacterial inosamine-phosphate amidi- 
notransferases [9-l 11. After introduction of some gaps to 
accommodate the different length of the proteins, about 
36% of the amino acid residues were identical between 
the mammalian and the somewhat shorter bacterial pro- 
teins (Fig. 5). About 15% of the changes were conserva- 
tive amino acid replacements which maintained the gen- 
eral properties (i.e. hydrophobic, acidic or basic) in all 
four sequences. 
In both mammalian and bacterial amidinotrans- 
ferases, a cysteine residue has been identified which is 
involved in the transfer of the amidine from arginine to 
the respective acceptor molecule by formation of a cova- 
lent isothiourea intermediate [24]. Therefore it was inter- 
esting to compare the cysteine pattern of both types of 
enzyme (Fig. 5). While the mature mammalian amidi- 
notransferases have 8 cysteines, the bacterial enzymes 
have only 3 (strB1) and 6 (strB2). Only 1 (strB1) or 2 
(strB2) of these coincide with cysteines in the mammalian 
enzyme sequences. Because the STRB2 protein actually 
did not show the amidinotransferase activity [l l] the 
STRBI protein with demonstrated enzymatic activity is 
probably more relevant for this comparison. The strB1 
sequence shows only 1 cysteine ((3352, Fig. 5) coinciding 
with a cysteine in the mammalian sequences. The strB2 
sequence does not have a cysteine in this position or in 
the immediate neighbourhoud. Thus this cysteine would 
be a prime candidate for the putative active site cysteine. 
Since the active cysteine can be labeled radioactively [24] 
it should be possible to locate it experimentally within 
the sequences presented in the present report. 
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